BriaCell Therapeutics (BCTX) saw its stock price climb significantly on Wednesday, fueled by impressive results from its Phase 2 clinical study. The study, which focused on Bria-IMT in combination with an immune checkpoint inhibitor (CPI) for late-stage metastatic breast cancer, showcased promising overall survival data.
The company reported a median overall survival of 15.6 months for patients treated with Bria-IMT since 2022. This figure stands in stark contrast to the 6.7-9.3 months survival reported in the literature for similar patients treated with other methods. Importantly, these patients are being treated with the same Bria-IMT formulation currently being used in BriaCell’s ongoing Phase 3 pivotal study in metastatic breast cancer.
This latest data represents a substantial improvement over BriaCell’s previous median overall survival of 13.4 months reported in December 2023.
“The Bria-IMT regimen is the only investigational drug we have seen to show these impressive survival numbers in heavily pre-treated metastatic breast cancer patients who have failed numerous prior treatments, including immune checkpoint inhibitors and antibody-drug conjugates,” stated Giuseppe Del Priore, BriaCell’s Chief Medical Officer.
The Phase 2 study included 54 patients with heavily pre-treated metastatic breast cancer (an average of 6 prior treatments) who received the Bria-IMT regimen and an immune checkpoint inhibitor.
As of Wednesday’s closing bell, BCTX stock was up a remarkable 213.1% at $1.94. These positive results are a significant step forward for BriaCell Therapeutics and the fight against metastatic breast cancer.
